1. Home
  2. CRNX
  3. CRNX News

Latest Crinetics Pharmaceuticals Inc. (CRNX) News on February 22, 2025

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
CRNX

GlobeNewswire

2 days ago

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

CRNX

MT Newswires

11 days ago

TD Cowen Initiates Crinetics Pharmaceuticals at Buy

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

12 days ago

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
CRNX

GlobeNewswire

16 days ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Crinetics Pharmaceuticals, Inc. (CRNX): One of January’s Biggest Losers
CRNX

Insider Monkey

17 days ago

Crinetics Pharmaceuticals, Inc. (CRNX): One of January’s Biggest Losers

CRNX

MT Newswires

18 days ago

Wolfe Research Initiates Coverage on Crinetics Pharmaceuticals With Peer Perform Rating

What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)?
CRNX

Insider Monkey

24 days ago

What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)?

CRNX

MT Newswires

a month ago

Jefferies Upgrades Crinetics Pharmaceuticals to Buy From Hold, $55 Price Target

Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
CRNX

Insider Monkey

a month ago

Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential
CRNX

Insider Monkey

a month ago

Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

a month ago

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX

MT Newswires

a month ago

Crinetics Shares Fall After Reporting 'Positive' Phase 2 Results for Congenital Adrenal Hyperplasia Treatment

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
CRNX

GlobeNewswire

a month ago

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
CRNX

GlobeNewswire

2 months ago

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
CRNX

GlobeNewswire

2 months ago

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

2 months ago

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX

MT Newswires

2 months ago

Crinetics Pharmaceuticals Says US FDA Accepts NDA for Paltusotine to Treat Acromegaly

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
CRNX

GlobeNewswire

2 months ago

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
CRNX

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
CRNX

GlobeNewswire

3 months ago

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)
CRNX

Simply Wall St.

3 months ago

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
CRNX

GuruFocus.com

3 months ago

Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

CRNX

MT Newswires

3 months ago

Crinetics Pharmaceuticals Q3 Net Loss Narrows

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
CRNX

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
CRNX

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week
CRNX

Simply Wall St.

4 months ago

Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week

State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals
CRNX

GuruFocus.com

4 months ago

State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
CRNX

GlobeNewswire

4 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

4 months ago

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Morning Movers: Arcadium Lithium surges after deal to be acquired
CRNX

TipRanks

4 months ago

Morning Movers: Arcadium Lithium surges after deal to be acquired

Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
CRNX

GuruFocus.com

4 months ago

Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

CRNX

MT Newswires

4 months ago

Update: Crinetics Pharmaceuticals Prices $500 Million Stock Offering

CRNX

MT Newswires

4 months ago

Crinetics Pharmaceuticals Prices $500 Million Stock Offering

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
CRNX

GlobeNewswire

4 months ago

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

CRNX

MT Newswires

4 months ago

Crinetics Pharmaceuticals Plans $400 Million Stock Sale

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
CRNX

GlobeNewswire

4 months ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

CRNX

MT Newswires

5 months ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $785,306, According to a Recent SEC Filing

CRNX

MT Newswires

5 months ago

Crinetics Pharmaceuticals Files New Drug Application for Acromegaly Treatment

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
CRNX

GlobeNewswire

5 months ago

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
CRNX

GuruFocus.com

5 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

5 months ago

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now
CRNX

Insider Monkey

6 months ago

Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
CRNX

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...
CRNX

GuruFocus.com

6 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...
CRNX

GuruFocus.com

6 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth
CRNX

Simply Wall St.

6 months ago

We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth

CRNX

MT Newswires

6 months ago

Oppenheimer Trims Crinetics Pharmaceuticals Price Target to $73 From $74, Maintains Outperform Rating

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
CRNX

Zacks

6 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
CRNX

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
CRNX

GlobeNewswire

6 months ago

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
CRNX

Zacks

7 months ago

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline

Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CRNX

Zacks

7 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
CRNX

GuruFocus.com

7 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
CRNX

GlobeNewswire

7 months ago

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

CRNX

MT Newswires

7 months ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $1,485,000, According to a Recent SEC Filing

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
CRNX

GuruFocus.com

7 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

7 months ago

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX

MT Newswires

7 months ago

JPMorgan Raises Price Target on Crinetics Pharmaceuticals to $54 From $47, Maintains Overweight Rating

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
CRNX

GuruFocus.com

8 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

CRNX

MT Newswires

8 months ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $434,435, According to a Recent SEC Filing

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
CRNX

GlobeNewswire

8 months ago

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...
CRNX

GuruFocus.com

8 months ago

Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

8 months ago

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
CRNX

Business Wire

8 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
CRNX

GlobeNewswire

8 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23
CRNX

GlobeNewswire

8 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
CRNX

Simply Wall St.

8 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May
CRNX

Reuters

8 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
CRNX

AFP

8 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed
CRNX

PR Newswire

8 months ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
CRNX

GlobeNewswire

8 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

CRNX

MT Newswires

9 months ago

Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating

Crinetics Unveils 'Stunning' Results In Highly Anticipated Study
CRNX

Investor's Business Daily

9 months ago

Crinetics Unveils 'Stunning' Results In Highly Anticipated Study

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
CRNX

GlobeNewswire

9 months ago

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
CRNX

GlobeNewswire

9 months ago

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Shareholders Will Probably Not Have Any Issues With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
CRNX

Simply Wall St.

9 months ago

Shareholders Will Probably Not Have Any Issues With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...
CRNX

GuruFocus.com

9 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
CRNX

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

CRNX

MT Newswires

9 months ago

Morgan Stanley Raises Price Target on Crinetics Pharmaceuticals to $70 From $50, Maintains Overweight Rating

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
CRNX

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript
CRNX

Insider Monkey

9 months ago

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript

Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) have seen solid returns of 196% over the past three years
CRNX

Simply Wall St.

9 months ago

Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) have seen solid returns of 196% over the past three years

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX

MT Newswires

9 months ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing

Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results
CRNX

GuruFocus.com

9 months ago

Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
CRNX

Zacks

9 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates

CRNX

MT Newswires

9 months ago

Crinetics Pharmaceuticals Q1 Net Loss Widens

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
CRNX

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
CRNX

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

CRNX

MT Newswires

10 months ago

Piper Sandler Adjusts Price Target on Crinetics Pharmaceuticals to $97 From $56, Maintains Overweight Rating

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
CRNX

GlobeNewswire

10 months ago

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

10 months ago

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)
CRNX

GuruFocus.com

a year ago

Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)

Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...
CRNX

GuruFocus.com

a year ago

Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...

Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)
CRNX

GuruFocus.com

a year ago

Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
CRNX

Zacks

a year ago

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares
CRNX

GuruFocus.com

a year ago

Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
CRNX

Zacks

a year ago

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?

Share on Social Networks: